Search Results for "Salvat Pherma"
Original Source: Laboratorios Salvat, S.A
SALVAT forms part of an independent, wholly Spanish owned, pharmaceutical group whose raison d’être lies in the defence and maintenance of health and their conviction that biomedical research is an absolute necessity for the future of the pharmaceutical industry.R&D requires the investment of considerable resources that do not always produce a good return, but at the same time, R&D is the only road towards the future. In SALVAT, research is perhaps the most vocational activity, while at the same time, be...
Matching Channels
None
Matching News
Positive Ph IIb results for SALVAT's tarafenacin in overactive bladder
Spanish drugmaker Laboratorios SALVAT and its South Koran partner Kwang Dong Pharmaceutical have released positive results of the Phase IIb clinical trial for tarafenacin (SVT-40776), a new drug under...
Laboratorios SALVAT S.A. (SALVAT) and Kwang Dong Pharmaceutical Co. Ltd (Kwang Dong) today announced the successful completion of the Phase IIb clinical trial for Tarafenacin, a n...
S. Korea's Kwan Dong Says OAB Drug Shown Successful In Phase II Trials
Kwan Dong Pharmaceutical of South Korea and Laboratorios Salvat of Spain announced success in a Phase II trial of tarafenacin as a treatment for overactive bladder syndrome.
Matching PubMed Articles
A Monte Carlo program for the analysis of low-energy electron tracks in liquid water.
A Monte Carlo code for the event-by-event simulation of electron transport in liquid water is presented. The code, written in C++, can accommodate different interaction models. Currently it implements...
